All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Patients with multiple myeloma (MM) often experience symptoms which significantly impact their quality of life (QoL), including pain, fatigue, and nausea as well as adverse effects from commonly used treatments. In later lines of therapy, QoL tends to further deteriorate, highlighting maintenance or improvement of QoL as a key goal for therapy.1
Here, we summarize a publication by Mohty et al.1 in the British Journal of Haematology on patient-reported outcomes (PROs) following treatment with elranatamab for relapsed/refractory (RR)MM in the phase II MagnetisMM-3 clinical trial.
The Multiple Myeloma Hub has previously provided coverage of the MagnetisMM trials.
Figure 1. Change in symptoms reported in A BCMA-naïve and B BCMA-exposed patients treated with elranatamab over time*
C, cycle; D, day.
*Adapted from Mohty, et al.1
Key learnings1 |
---|
|
Subscribe to get the best content related to multiple myeloma delivered to your inbox